U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday.Shares of Abbott Laboratories ABT fell sharply in pre-market trading after the company issued third-quarter adjusted EPS guidance below estimates.Abbott posted adjusted earnings of $1.26 per share, beating market estimates of $1.25 per share. The company's sales came in at $11.142 billion versus expectations of $11.068 billion.Abbott Laboratories said it sees third-quarter adjusted EPS of $1.28 to $1.32, ...

ROSELAND, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the initiation of commercial sales of its CompuFlo® Epidural System and related disposables at The Painless Center, located in Tenafly, New Jersey. The Painless Center is led by Chi-Shin Jason Chiu, MD, a double board-certified physician in Pain Management and Anesthesiology. A respected figure in ...

KIRKLAND, Wash., July 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, announced today that it is a 2025 Top Workplaces Industry winner by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplaces program has a 17-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. Top Workplaces Industry awards celebra ...

Core Insights - Nuwellis, Inc. has announced the termination of its REVERSE-HF clinical trial to focus resources on outpatient markets with higher potential for impact and growth [1][2] - The company aims to redirect investments towards outpatient heart failure, pediatric, and critical care areas, anticipating savings of approximately $4.0 million over the next 2.5 years from this decision [2][3] Company Strategy - The decision to terminate the REVERSE-HF trial is part of a strategic commitment to prioritize areas that demonstrate the greatest potential for patient impact and business growth [1][2] - Nuwellis is experiencing increasing demand for its ultrafiltration therapy in hospital-based outpatient heart failure programs, indicating a shift in focus towards this high-potential area [2] Clinical Trial Details - The REVERSE-HF trial began enrolling patients in 2022 and had enrolled 167 patients at the time of termination [3] - The company plans to collaborate with the steering committee and biostatisticians to derive statistical value from the existing data for future clinical publications [3] Product Information - The Nuwellis SmartFlow device remains on the market as an FDA-cleared treatment for fluid overload, and the termination of the trial was not related to device performance or patient safety concerns [4][6] - The Aquadex SmartFlow system is designed for ultrafiltration therapy, indicated for both adult and pediatric patients suffering from hypervolemia [6]

Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1 Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26 Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increase Reported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increaseABBOTT PARK, Ill., July 17, ...

The Company welcomes CMS’ efforts to reform skin substitute payment policy and will continue to engage with CMS and other stakeholders to optimize the proposed changesPOMPANO BEACH, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, comments on the Centers for Medicare and Medicaid Services (“CMS”) release of the Calendar Year (“CY”) 2 ...

Company Performance - United Airlines reported Q2 earnings, missing both revenue and earnings estimates, with earnings of $2.97 per share compared to the expected $3.86 and the previous year's $4.14 [3] - Revenues for United Airlines were $15.2 billion, falling short of the anticipated $15.36 billion [3] - Despite the earnings miss, United Airlines saw increases in cabin revenues (+5.6%) and cargo revenues (+3.8%), along with an 8.7% growth in its loyalty program [4] Market Overview - The Dow closed up +231 points (+0.53%), the S&P 500 increased by +19 points (+0.32%), and the Nasdaq rose by +52 points (+0.25%) [2] - The small-cap Russell 2000 gained +21 points (+0.99%) during the session [2] - Bond yields showed mixed movements, with the 10-year yield rising to +4.45% and the 2-year yield decreasing to +3.89% [2] Economic Indicators - Industrial Production for June matched the previous month's revised figure, showing a +0.7% increase for the seventh consecutive month, with manufacturing up +0.8% and mining up +1.6% [5] - Capacity Utilization was reported at 77.6%, exceeding the expected 77.4% and the previous month's revised 77.5% [6]

Company Overview - Senseonics Holdings, Inc. is a medical technology company focused on developing and manufacturing long-term implantable continuous glucose monitoring (CGM) systems for diabetes management [3] - The company's CGM systems, Eversense 365 and Eversense E3, feature a small sensor that is implanted under the skin and communicates with a smart transmitter worn externally, sending glucose data to a mobile app every 5 minutes [3] Financial Results Announcement - Senseonics plans to release its second quarter 2025 financial results after market close on August 6, 2025 [1] - A conference call to review the company's performance for the second quarter 2025 will take place at 4:30 p.m. (Eastern Time) on the same day, with a webcast available on the company's website [2]

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [3] - The company’s key products include the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX Platform, and StratX® Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [3] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is commercially available in over 25 countries [3] Upcoming Financial Results - Pulmonx will release its financial results for the second quarter of 2025 after the close of trading on July 30, 2025 [1] - Following the results announcement, company management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results [1]

BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) ...